Trastuzumab Decorated Nanoparticles for Targeted Chemotherapy of Breast Cancer

Abstract:

Article Preview

Nanoparticles (NPs) of biodegradable polymers as a drug delivery system formulate drug devoid of harmful adjuvant, realize controlled drug release and achieve better therapeutic efficacy than pristine agent. However, the low selectivity of NPs towards cancer cells hinders the advantages of NP formulation for efficient chemotherapy. The novel system of paclitaxel-loaded, trastuzumab-decorated poly(D,L-lactide-co-glycolide)/montmorillonite(PLGA/MMT) NPs for targeted drug delivery was developed. Paclitaxel was used as a prototype drug with excellent therapeutic effects against a wide spectrum of cancers. Trastuzumab is a humanized monoclonal antibody directed against the human epidermal growth factor receptor-2(HER2), which overexpresses in 25-30% breast cancers. Moreover, synergistic effects have been found in combination of trastuzumab with paclitaxel. As a potent detoxifier, the medical clay MMT can adsorb toxins and reduce side effects. The drug delivery system represents a new concept in developing drug delivery systems and can achieve functions such as to formulate anticancer drugs with no harmful adjuvant; to reduce side effects caused by formulated drugs; to have synergistic therapeutic effects; and to achieve targeted chemotherapy for HER2-positive breast cancer

Info:

Periodical:

Edited by:

Pietro VINCENZINI and Danilo DE ROSSI

Pages:

160-165

DOI:

10.4028/www.scientific.net/AST.57.160

Citation:

B. F. Sun and S. S. Feng, "Trastuzumab Decorated Nanoparticles for Targeted Chemotherapy of Breast Cancer", Advances in Science and Technology, Vol. 57, pp. 160-165, 2008

Online since:

September 2008

Export:

Price:

$35.00

In order to see related information, you need to Login.

In order to see related information, you need to Login.